Novartis and Eisai end Japan COPD alliance
This article was originally published in Scrip
Executive Summary
Novartis and Eisai have decided to discontinue their co-promotion alliance in Japan for three Novartis inhaled products for the treatment of chronic obstructive pulmonary disease (COPD), following a review of the tie-up and sales strategies for the products.